Apellis Pharmaceuticals, Inc. (APLS)
$41.03+0.00%Close
BUYBULL · day 33
Key stats
- Market cap
- $5.3B
- Beta
- -0.25
- P/E (TTM)
- 38.71
- 1W
- +0.00%
- 1M
- +0.39%
- vs SPY 1W
- -1.16%
- vs SPY 1M
- -2.60%
Industry peers
FMP comparable companies · ranked by market cap
- KNSABUYKiniksa Pharmaceuticals International, plc$5.8BBULLQ 24$76.31+1.31%
- CDTXCidara Therapeutics, Inc.$5.6B$221.38
- SRRKSELLScholar Rock Holding Corporation$5.2BCRISISQ 22$43.40-0.02%
- ADPTBUYAdaptive Biotechnologies Corporation$4.8BCRISISQ 6$29.84+1.53%
- CPRXBUYCatalyst Pharmaceuticals, Inc.$3.9BBULLQ 20$31.49+0.00%
- IDYASELLIDEAYA Biosciences, Inc.$3.6BBEARQ 25$38.06+0.14%
- BEAMBUYBeam Therapeutics Inc.$2.6BRECOVERYQ 14$25.67+4.47%
- RXRXBUYRecursion Pharmaceuticals, Inc.$2.5BRECOVERYQ 1$4.78+10.38%
- MLYSSELLMineralys Therapeutics, Inc.$2.1BCRISISQ 19$23.30+4.42%
- AGIOSELLAgios Pharmaceuticals, Inc.$1.9BRECOVERYQ 4$31.25-0.34%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on APLS?
- LOPJLB’s latest quantitative signal on Apellis Pharmaceuticals, Inc. (APLS) is BUY in a BULL regime. Signals are updated daily.
- What market regime is APLS in?
- Apellis Pharmaceuticals, Inc. (APLS) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Apellis Pharmaceuticals, Inc. (APLS) do?
- Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical ev…